Email this article COVID-19 and cardiovascular diseases
- Authors: Chazova I.E.1, Mironova O.I.2
-
Affiliations:
- National Medical Research Center for Cardiology
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 92, No 9 (2020)
- Pages: 4-7
- Section: Editorial article
- URL: https://ogarev-online.ru/0040-3660/article/view/46843
- DOI: https://doi.org/10.26442/00403660.2020.09.000742
- ID: 46843
Cite item
Full Text
Abstract
First cases of new coronavirus infection were registered in December 2019. The COVID-19 outbreak was declared a global pandemic. COVID-19 is much more dangerous for people older than 65. It is well known that cardiovascular diseases are more affecting older patients as well. The potentially dangerous combination of the new infection and different cardiovascular diseases has become a crucial problem of cardiology in 2020.
Full Text
##article.viewOnOriginalSite##About the authors
I. E. Chazova
National Medical Research Center for Cardiology
Email: mironova_o_yu@staff.sechenov.ru
ORCID iD: 0000-0002-9822-4357
акад. РАН, д.м.н., проф., зам. ген. дир. по научно-экспертной работе ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowO. I. Mironova
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: mironova_o_yu@staff.sechenov.ru
ORCID iD: 0000-0002-5820-1759
к.м.н., доц. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
Russian Federation, MoscowReferences
- Shi S, Qin M, Shen B, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;1-8. doi: 10.1001/jamacardio.2020.0950
- Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: Results from the China hypertension survey, 2012–2015. Circulation. 2018;137(22):2344-56. doi: 10.1161/CIRCULATIONAHA. 117.032380
- Zhonghua Liu, Xing Bing, Xue Za Zhi. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. 2020 Feb;41(2):145-51. doi: 10.3760/cma. j.issn.0254-6450.2020.02.003
- Torlasco C, Faini A, Makil E, et al. Nation-wide hypertension screening in Italy: data from May Measurements Month 2017 – Europe. Eur Hear J Suppl. 2019;21(Suppl._D):D66-70. doi: 10.1093/eurheartj/suz058
- Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: Systematic review and meta-analysis. BMJ. 2012;345(7868):1-20. doi: 10.1136/bmj.e4260
- Yang G, Tan Z, Zhou L, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. medRxiv. 2020 Jan. doi: 10.1101/2020.03.31.20038935
- Roche JA. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. Faseb J. 2020;34:7265-9. doi: 10.1096/fj.202000967
- Chen Dong, Li X, Song Q, et al. Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19). medRxiv. 2020 Jan. doi: 10.1101/2020.02.27.20028530
- Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;531-8. doi: 10.1007/s00392-020-01626-9
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
- Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832. doi: 10.1016/j.jns.2020.116832
Supplementary files
